ZFIN Image: Missinato et al., 2018, Fig. S9

Image

Figure Caption

Fig. S9

BCI215 is specific for Dusp6 (A) Cryosections of WT and dusp6^pt30a/+ hearts at 7 dpa injected for 6 days with DMSO (WT n=33; dusp6^pt30a/+ n=17), or 0.25 mg/Kg of BCI215 (WT n=7; dusp6^pt30a/+ n=11), stained for Mef2c and PCNA. (B) Quantification of cardiomyocyte proliferation in hearts injected with BCI215, or vehicle DMSO. Sub-optimal dose of BCI215 does not affect cardiomyocyte proliferation in WT hearts, but increases cardiomyocyte proliferation in dusp6^pt30a/+ hearts. **p<0.01; n.s.=not significant. One-way ANOVA. (C) Cryosections of WT and dusp6^pt30a/+ hearts at 7 dpa injected with DMSO (WT n=25; dusp6^pt30a/+ n=15), or 0.5 mg/Kg of BCI215 (WT n=21; dusp6^pt30a/+ n=8), stained for Mef2c and PCNA. (D) Quantification of cardiomyocyte proliferation. Optimal dose of BCI215 increases cardiomyocyte proliferation in WT hearts but it does not affect cardiomyocyte proliferation in dusp6^pt30a/+ hearts ****p<0.0001; n.s.=not significant. One-way ANOVA. Scale bars, 100 μm.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Development